GT Biopharma Initiates Cohort 3 in Phase 1 Trial for GTB-3650
The first patient in Cohort 3 of the GTB-3650 trial has successfully completed one week of treatment following an encouraging safety review of the previous cohort. This important milestone reflects the company's commitment to advancing innovative therapeutic solutions without any observed safety or tolerability issues.
GT Biopharma, Inc. (NASDAQ: GTBP), a leader in immuno-oncology research, has started dosing patients in Cohort 3 of its Phase 1 dose escalation trial, which is designed to assess the efficacy of GTB-3650 for individuals with relapsed or refractory (r/r) CD33 expressing hematologic malignancies.
Overview of the Phase 1 Trial
This trial scrutinizes the performance of GTB-3650, the company's second-generation TriKE that aims to harness the body’s own immune system. The completed Cohorts 1 and 2 demonstrated promising preliminary outcomes, showing that GTB-3650 activates natural killer (NK) cells and promotes their expansion, crucial elements in the fight against cancer.
Initial data from the first four patients in the trial highlight heightened immune activity, revealing the potential of GTB-3650 to provide a significant therapeutic benefit. The company anticipates the first Phase 1 results will be disclosed later, following the completion of more dose cohorts.
Trial Design and Patient Assessment
The trial aims to enroll approximately 14 patients over seven cohorts. Each cohort will receive a dose of GTB-3650 in cycles lasting two weeks each, followed by a two-week rest, continuing for up to four months based on observed clinical benefits. Throughout this period, the study will evaluate various parameters including safety, pharmacokinetics, pharmacodynamics, and the in vivo expansion of NK cells.
This multi-faceted approach ensures a comprehensive understanding of how GTB-3650 interacts with the body while offering hope to patients with significant unmet medical needs in the realm of hematologic malignancies.
About GT Biopharma and Its Innovations
GT Biopharma is dedicated to developing pioneering immuno-oncology therapeutics through its proprietary TriKE platform, which uniquely enhances the cancer-fighting abilities of NK cells derived from patients' immune systems. The firm has secured an exclusive worldwide license from the University of Minnesota to develop therapies using this innovative technology.
Through advancements like the TriKE platform, GT Biopharma is positioning itself at the forefront of cancer treatment, offering new hope to patients battling difficult-to-treat cancers.
Contact Information for Investor Relations
For those seeking more information or having inquiries regarding the company's ongoing projects or investments, please reach out to:
LifeSci Advisors
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com
Phone: 212-915-2577
Frequently Asked Questions
What is the GTB-3650 trial about?
The GTB-3650 trial aims to evaluate the safety and effectiveness of GTB-3650 in treating specific hematologic malignancies.
What promising results have been observed so far?
Initial results from earlier cohorts have shown promising immune responses with activation and expansion of NK cells.
How many cohorts will the trial include?
The trial is structured with up to seven cohorts, enrolling approximately 14 patients in total.
What technology does GT Biopharma use in its treatments?
GT Biopharma utilizes its proprietary TriKE platform that enhances the natural abilities of NK cells to target and destroy cancer cells.
How can investors get in touch with GT Biopharma?
Investors can contact LifeSci Advisors via email at cdavis@lifesciadvisors.com for inquiries and more information.
